CMS Shouldn’t Eliminate TENS Coverage For Back Pain, Say Clinical Groups
This article was originally published in The Gray Sheet
You may also be interested in...
CMS To Scrutinize TENS For Back Pain In National Coverage Analysis
CMS has opened a national coverage analysis for the use of transcutaneous electrical nerve stimulation to treat chronic low back pain, citing a specialty society guideline that concludes the treatment is ineffective.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.